Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

A newly developed radiolabeled antibody that targets the cancer antigen IL13Rα2 has been found to be highly specific, binding ...

In this study, as the focus was broad pathogenic antibody profiling, we did not test antibody reactivity to autoantigens such as CRYAB and only speculated on possible cross-reactivity based on ...

The team created a novel tick antigen library housing over 3,000 different proteins, testing each to create a target cocktail ...

Traumatically injured women are considerably less likely to receive whole blood transfusions within the first four hours of injury compared to men, despite whole blood being associated with reduced ...

I f you can't quite remember what your blood type is -- don't worry. That just means you're among the 33% of Americans who ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

OXFORD, UK I April 9, 2025 I Infinitopes Ltd today announces that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Clinical Trial ...

The test, which can be used at home, appeared to perform better than the current method for assessing prostate cancer risk, according to a new study. The prostate-specific antigen test is a blood test ...

Solu Therapeutics, a company developing a new type of antibody drug ... based Solu has already begun dosing patients in a Phase 1 test of lead program STX-0712 in resistant or refractory chronic ...